4,871 results on '"Braunwald, Eugene"'
Search Results
102. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.
103. Foreword
104. Preface
105. Hypertrophic Cardiomyopathy: The Past, the Present, and the Future
106. Baseline Characteristics of the VANISH Cohort
107. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial
108. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
109. Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations
110. Hypertrophic Cardiomyopathy: The Past, the Present, and the Future
111. Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation
112. Mitochondrial cardiomyopathy: a fertile field for research
113. Geographic Differences in Patients With Acute Myocardial Infarction in The PARADISE‐MI Trial
114. EDOXABAN 30 MG VS WARFARIN IN 2,406 PATIENTS AGE ≥80 YEARS: A RANDOMIZED ANALYSIS FROM ENGAGE AF-TIMI 48
115. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
116. Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial
117. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P–TIMI 50 Trial
118. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure
119. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
120. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50)
121. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial
122. Impact of ADCY9 Genotype on Response to Anacetrapib
123. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial
124. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
125. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48
126. Medication Discontinuation in the IMPROVE-IT Trial
127. Foreword
128. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.
129. Air pollution: challenges and opportunities for cardiology
130. Neutrophil-Lymphocyte Ratio and Clinical Outcomes in 19,697 Patients with Atrial Fibrillation: Analyses from ENGAGE AF-TIMI 48 Trial
131. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
132. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
133. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
134. The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure
135. The war against heart failure: the Lancet lecture
136. Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome
137. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54
138. New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial
139. Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial
140. Triglycerides: the past, the present, and the future.
141. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
142. Inhibitors of factor XI: game changers of anti-thrombotic therapy?
143. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial
144. Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial
145. Short interfering RNA: a rapidly developing drug class
146. Atrial amyloidosis: mechanisms and clinical manifestations
147. A polygenic risk score predicts atrial fibrillation in cardiovascular disease
148. Glucose–Insulin–Potassium Therapy for Acute Myocardial Infarction: 50 Years On and Time for a Relook
149. Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation: The ENGAGE AF–TIMI 48 Trial
150. The ten advances that have defined modern cardiology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.